The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A novel test shows promise for finding cervical adenocarcinoma, which is difficult to find.

2.

Researchers publish action plan to address appendiceal cancer enigmas

3.

AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns

4.

Underprescribed for Alcohol Use Disorder is pharmacotherapy.

5.

Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot